National Centre for Clinical Research on Emerging Drugs
About
In recent decades, authors affiliated with National Centre for Clinical Research on Emerging Drugs have published 1.5k papers, which have received a total of 77.1k indexed citations.
Scholars at this organization have produced 682 papers in Epidemiology, 573 papers in Infectious Diseases and 323 papers in Virology on the topics of Prevention and Treatment of HIV/AIDS Infection (434 papers), HIV Research and Treatment (320 papers) and HIV, Drug Use, Sexual Risk (306 papers). Their work is cited by papers focused on Epidemiology (32.0k citations), Infectious Diseases (26.0k citations) and Virology (15.6k citations). Authors at National Centre for Clinical Research on Emerging Drugs collaborate with scholars in Australia, United States and United Kingdom and have published in prestigious journals including New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet. Some of National Centre for Clinical Research on Emerging Drugs's most productive authors include John Kaldor, Matthew Law, David A. Cooper, Gregory J. Dore and Andrew E. Grulich.
In The Last Decade
side by side view
Countries citing scholars working at National Centre for Clinical Research on Emerging Drugs
Since SpecializationCitations
Explore institutions with similar magnitude of impact
Breakdown of academic impact, for scholars at International Water Management Institute Breakdown of academic impact, for scholars at Institute for Cancer Prevention Breakdown of academic impact, for scholars at Yorkshire Cancer Research Breakdown of academic impact, for scholars at Cancer Council Queensland Breakdown of academic impact, for scholars at Angeles Clinic and Research Institute Breakdown of academic impact, for scholars at Center for Neuro-Oncology Breakdown of academic impact, for scholars at Boston Biomedical Research Institute Breakdown of academic impact, for scholars at International Institute for Management Development